Results 21 to 30 of about 235,727 (237)

Detection of Early Diffuse Myocardial Fibrosis and Inflammation in Chagas Cardiomyopathy with T1 Mapping and Extracellular Volume. [PDF]

Radiol Cardiothorac Imaging, 2023
Purpose To evaluate myocardial T1 mapping and extracellular volume (ECV) parameters in different stages of Chagas cardiomyopathy and determine whether they are predictive of disease severity and prognosis.
Melo RJL, Assunção AN, Morais TC, Nomura CH, Scanavacca MI, Martinelli-Filho M, Ramires FJA, Fernandes F, Ianni BM, Mady C, Rochitte CE.   +10 more
europepmc   +2 more sources

Omega-3 supplementation on inflammatory markers in patients with chronic Chagas cardiomyopathy: a randomized clinical study [PDF]

Nutrition Journal, 2017
Background Several studies have been focusing on the effect of omega-3 polyunsaturated fatty acids on modulation of inflammatory markers in several cardiopathies.
Paula Simplício da Silva, Mauro Felippe Felix Mediano, Gilberto Marcelo Sperandio da Silva, Patricia Dias de Brito, Claudia Santos de Aguiar Cardoso, Cristiane Fonseca de Almeida, Luiz Henrique Conde Sangenis, Roberta Olmo Pinheiro, Alejandro Marcel Hasslocher-Moreno, Pedro Emmanuel Alvarenga Americano do Brasil, Andrea Silvestre de Sousa   +10 more
doaj   +2 more sources

Mortality risk in chronic Chagas cardiomyopathy: a systematic review and meta‐analysis

ESC Heart Failure, 2021
Aims This study aimed to estimate the annual mortality risk and its determinants in chronic Chagas cardiomyopathy. Methods and results We conducted a systematic search in MEDLINE, Web of Science Core Collection, Embase, Cochrane Library, and LILACS ...
Sindhu Chadalawada, Anis Rassi Jr, Omar Samara, Anthony Monzon, Deepika Gudapati, Lilian Vargas Barahona, Peter Hyson, Stefan Sillau, Luisa Mestroni, Matthew Taylor, Maria daConsolação Vieira Moreira, Kristen DeSanto, Nelson I. Agudelo Higuita, Carlos Franco‐Paredes, Andrés F. Henao‐Martínez   +14 more
doaj   +2 more sources

Risk Factors for Progression to Chronic Chagas Cardiomyopathy: A Systematic Review and Meta-Analysis. [PDF]

Am J Trop Med Hyg, 2023
Approximately one-third of people with chronic Trypanosoma cruzi infection develop Chagas cardiomyopathy, which carries a poor prognosis. Accurate prediction of which individuals will go on to develop Chagas cardiomyopathy remains elusive. We performed a
Cutshaw MK, Sciaudone M, Bowman NM.
europepmc   +2 more sources

GWAS loci associated with Chagas cardiomyopathy influences DNA methylation levels

PLoS Neglected Tropical Diseases, 2021
A recent genome-wide association study (GWAS) identified a locus in chromosome 11 associated with the chronic cardiac form of Chagas disease. Here we aimed to elucidate the potential functional mechanism underlying this genetic association by analyzing ...
Desiré Casares-Marfil, Martin Kerick, Eduardo Andrés-León, Pau Bosch-Nicolau, Israel Molina, Chagas Genetics CYTED Network, Javier Martin, Marialbert Acosta-Herrera   +7 more
doaj   +3 more sources

Mechanisms behind the high mortality rate in chronic Chagas cardiomyopathy: Unmasking a three-headed monster. [PDF]

Eur J Heart Fail
Chagas disease is a neglected tropical disease caused by the parasite Trypanosoma cruzi. Chronic Chagas cardiomyopathy (CCC), the most severe form of target organ involvement in Chagas disease, is characterized by a complex pathophysiology and a unique ...
Echeverría LE, Serrano-García AY, Rojas LZ, Berrios-Bárcenas EA, Gómez-Mesa JE, Gómez-Ochoa SA.   +5 more
europepmc   +2 more sources

Chronic Chagas cardiomyopathy: a review of the main pathogenic mechanisms and the efficacy of aetiological treatment following the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial

Memorias do Instituto Oswaldo Cruz, 2017
Chagas cardiomyopathy is the most frequent and most severe manifestation of chronic Chagas disease, and is one of the leading causes of morbidity and death in Latin America.
Anis Rassi Jr, José Antonio Marin Neto, Anis Rassi   +2 more
doaj   +2 more sources

Long-term Survival Following Heart Transplantation for Chagas Versus Non-Chagas Cardiomyopathy: A Single-center Experience in Northeastern Brazil Over 2 Decades

Transplantation Direct, 2022
Background. Data on post–heart transplant (HT) survival of patients with Chagas cardiomyopathy (CC) are scarce. We sought to evaluate post-HT survival in patients with CC as compared with other causes of heart failure across different eras of HT. Methods.
Jefferson L. Vieira, MD, MBA, PhD, Maria G. V. Sobral, RN, Francisco Y. Macedo, MD, PhD, Raquel S. Florêncio, RN, Germana P. L. Almeida, MD, Glauber G. Vasconcelos, MD, Juliana R. Fernandes, MD, Laura L. E. Marinho, MD, Daniel F. M. Trompieri, MD, Tilak K. R. Pasala, MD, Juan A. C. Mejia, MD, João D. Souza-Neto, MD, PhD   +11 more
doaj   +2 more sources

Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management A Scientific Statement From the American Heart Association

Circulation, 2018
Background: Chagas disease, resulting from the protozoan Trypanosoma cruzi, is an important cause of heart failure, stroke, arrhythmia, and sudden death. Traditionally regarded as a tropical disease found only in Central America and South America, Chagas
M. P. Nunes, A. Beaton, H. Acquatella, C. Bern, A. Bolger, L. E. Echeverría, W. Dutra, J. Gascón, C. Morillo, J. Oliveira-Filho, A. Ribeiro, J. Marin-Neto   +11 more
semanticscholar   +3 more sources

Amiodarone or Implantable Cardioverter-Defibrillator in Chagas Cardiomyopathy: The CHAGASICS Randomized Clinical Trial.

JAMA Cardiol
Key Points Question Are implantable cardioverter-defibrillators (ICDs) more effective than amiodarone hydrochloride for primary prevention of all-cause mortality and sudden cardiac death (SCD) in patients with chronic Chagas cardiomyopathy at moderate to
Martinelli-Filho M, Marin-Neto JA, Scanavacca MI, de Paola AAV, Medeiros PTJ, Owen R, Pocock SJ, de Siqueira SF, CHAGASICS investigators.   +8 more
europepmc   +2 more sources